| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 2.01B | 15.28 | 388.80 | 33.97% | 29.28% | 21.28% | 2.19% | 0.21 |
| ARGXargenx SE | 49.26B | 796.00 | 62.28 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.45B | 19.44 | 54 | 15.54% | 32.78% | 12.61% | 12.96% | 0.65 |
| GLPGGalapagos N.V. | 2.18B | 33.11 | 29.56 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.02B | 80.25 | 18.97 | 6.24% | 21.94% | 7.11% | 3.64% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.48B | 21.09 | -2.03 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.13B | 14.47 | -2.74 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.49B | 30.69 | -6.15 | -22.44% | 0.00 |
| Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.13M | 1.5M | 8.39M | 16.13M | 12.69M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 0.18% | -0.29% | 4.58% | 0.92% | -0.21% | -1% | - | - | - | - |
| Cost of Goods Sold | 14.66K | 12.67K | 18.24K | 35.02K | 40.19M | 41.29M | 0 | 0 | 86.17M | 0 |
| COGS % of Revenue | 0.01% | 0.01% | 0% | 0% | 3.17% | - | - | - | - | - |
| Gross Profit | 2.12M | 1.49M | 8.38M | 16.09M | -27.5M | -41.29M | 0 | 0 | -86.17M | 0 |
| Gross Margin % | 0.99% | 0.99% | 1% | 1% | -2.17% | - | - | - | - | - |
| Gross Profit Growth % | 0.18% | -0.3% | 4.62% | 0.92% | -2.71% | -0.5% | 1% | - | - | 1% |
| Operating Expenses | 17.31M | 23.84M | 27.1M | 45.95M | 13.03M | 16.64M | 96.61M | 110.87M | 54.28M | 188M |
| OpEx % of Revenue | 8.12% | 15.85% | 3.23% | 2.85% | 1.03% | - | - | - | - | - |
| Selling, General & Admin | 2.65M | 11.18M | 8.86M | 10.93M | 13.03M | 16.64M | 26.45M | 30.59M | 54.28M | 116.29M |
| SG&A % of Revenue | 1.24% | 7.43% | 1.06% | 0.68% | 1.03% | - | - | - | - | - |
| Research & Development | 14.66M | 12.67M | 18.24M | 35.02M | 40.19M | 41.29M | 70.17M | 80.28M | 86.17M | 71.71M |
| R&D % of Revenue | 6.87% | 8.42% | 2.17% | 2.17% | 3.17% | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -40.19M | -41.29M | 0 | 0 | -86.17M | 0 |
| Operating Income | -15.18M | -22.34M | -18.7M | -29.82M | -40.53M | -57.92M | -96.61M | -110.87M | -140.44M | -188M |
| Operating Margin % | -7.12% | -14.85% | -2.23% | -1.85% | -3.19% | - | - | - | - | - |
| Operating Income Growth % | -0.88% | -0.47% | 0.16% | -0.59% | -0.36% | -0.43% | -0.67% | -0.15% | -0.27% | -0.34% |
| EBITDA | -15.05M | -22.3M | -18.52M | -29.44M | -40.02M | -57.39M | -96.05M | -110.15M | -139.63M | -187.05M |
| EBITDA Margin % | -7.05% | -14.83% | -2.21% | -1.83% | -3.15% | - | - | - | - | - |
| EBITDA Growth % | -0.87% | -0.48% | 0.17% | -0.59% | -0.36% | -0.43% | -0.67% | -0.15% | -0.27% | -0.34% |
| D&A (Non-Cash Add-back) | 133K | 40K | 180K | 378K | 512K | 537K | 564K | 718K | 816K | 941K |
| EBIT | -15.18M | -22.34M | -18.7M | -29.82M | -40.53M | -57.92M | -81.31M | -95.09M | -135.1M | -174.27M |
| Net Interest Income | 50K | 36K | 82K | 1.4M | 1.83M | 903K | 1.09M | 2.23M | 0 | 650K |
| Interest Income | 50K | 36K | 82K | 1.4M | 1.83M | 903K | 1.09M | 2.23M | 0 | 6.43M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.79M |
| Other Income/Expense | 3.75M | 3.74M | 2.9M | 9.13M | 11.54M | 11.68M | 14.27M | 17.96M | 5.35M | 7.94M |
| Pretax Income | -11.44M | -18.6M | -15.8M | -20.69M | -28.99M | -46.24M | -82.34M | -92.91M | -135.1M | -180.05M |
| Pretax Margin % | -5.36% | -12.37% | -1.88% | -1.28% | -2.28% | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 124K | 124K | 0 | 0 | 0 | -8.45M | 3.39M |
| Effective Tax Rate % | 1% | 1% | 1% | 1.01% | 1% | 1% | 1% | 1% | 0.94% | 1.02% |
| Net Income | -11.44M | -18.6M | -15.8M | -20.82M | -29.12M | -46.24M | -82.34M | -92.91M | -126.64M | -183.44M |
| Net Margin % | -5.36% | -12.37% | -1.88% | -1.29% | -2.29% | - | - | - | - | - |
| Net Income Growth % | -0.58% | -0.63% | 0.15% | -0.32% | -0.4% | -0.59% | -0.78% | -0.13% | -0.36% | -0.45% |
| Net Income (Continuing) | -11.44M | -18.6M | -15.8M | -20.82M | -29.12M | -46.24M | -82.34M | -92.91M | -126.64M | -183.44M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.40 | -1.92 | -1.53 | -1.38 | -1.64 | -2.33 | -3.36 | -3.33 | -3.44 | -3.69 |
| EPS Growth % | 0.61% | 0.2% | 0.2% | 0.1% | -0.19% | -0.42% | -0.44% | 0.01% | -0.03% | -0.07% |
| EPS (Basic) | -2.40 | -1.92 | -1.53 | -1.38 | -1.64 | -2.33 | -3.36 | -3.33 | -3.44 | -3.69 |
| Diluted Shares Outstanding | 4.77M | 9.71M | 10.32M | 15.08M | 17.75M | 19.09M | 24.47M | 27.89M | 36.79M | 49.65M |
| Basic Shares Outstanding | 4.77M | 9.71M | 10.32M | 15.08M | 17.75M | 19.09M | 24.47M | 27.89M | 36.79M | 49.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 24.67M | 34.25M | 59.38M | 115.55M | 88.7M | 264.26M | 193.65M | 172.33M | 225.69M | 241.69M |
| Cash & Short-Term Investments | 21.76M | 30.95M | 51.05M | 100.81M | 67.71M | 248.93M | 166.2M | 149.38M | 210.4M | 187.65M |
| Cash Only | 21.76M | 30.95M | 51.05M | 32.01M | 15.79M | 50.59M | 30.73M | 56.24M | 31.79M | 98.64M |
| Short-Term Investments | 0 | 0 | 0 | 68.81M | 51.92M | 198.34M | 135.47M | 93.14M | 178.61M | 89M |
| Accounts Receivable | 356K | 2.55M | 6.83M | 11.31M | 16.53M | 11.72M | 16.81M | 18.64M | 10.87M | 15.14M |
| Days Sales Outstanding | 60.92 | 618.12 | 297.17 | 256.09 | 475.36 | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.21M |
| Total Non-Current Assets | 74K | 97K | 2.01M | 2.59M | 3.83M | 7.75M | 10.23M | 10.88M | 9.71M | 9.08M |
| Property, Plant & Equipment | 74K | 97K | 1.84M | 2.41M | 3.65M | 7.55M | 10.04M | 10.77M | 9.15M | 1.99M |
| Fixed Asset Turnover | 28.82x | 15.51x | 4.57x | 6.68x | 3.47x | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 199K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -199K | 0 | 173K | 173K | 178K | 200K | 193K | 106K | 567K | 7.09M |
| Total Assets | 24.75M | 34.34M | 61.39M | 118.13M | 92.53M | 272.01M | 203.88M | 183.2M | 235.4M | 250.77M |
| Asset Turnover | 0.09x | 0.04x | 0.14x | 0.14x | 0.14x | - | - | - | - | - |
| Asset Growth % | 2.72% | 0.39% | 0.79% | 0.92% | -0.22% | 1.94% | -0.25% | -0.1% | 0.28% | 0.07% |
| Total Current Liabilities | 3.25M | 3.02M | 23.22M | 18.05M | 7.72M | 9.77M | 11.58M | 15.03M | 22.81M | 45.17M |
| Accounts Payable | 1.01M | 1.15M | 1.43M | 2.86M | 1.68M | 1.98M | 3.64M | 4.82M | 9.11M | 4.88M |
| Days Payables Outstanding | 25.1K | 33.23K | 28.68K | 29.81K | 15.23 | 17.51 | - | - | 38.58 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 29K | 0 | 1000K | 1000K | 0 | 0 | 0 | 0 | 0 | 1000K |
| Other Current Liabilities | 1.49M | 0 | 0 | 0 | 0 | 3.51M | 4.17M | 4.21M | 6.69M | 0 |
| Current Ratio | 7.59x | 11.35x | 2.56x | 6.40x | 11.49x | 27.04x | 16.73x | 11.46x | 9.90x | 5.35x |
| Quick Ratio | 7.59x | 11.35x | 2.56x | 6.40x | 11.49x | 27.04x | 16.73x | 11.46x | 9.90x | 5.35x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.01M | 1.15M | 10.92M | 3.34M | 1.06M | 5.05M | 7.21M | 7.14M | 6.01M | 110.21M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 58K | 0 | 1.06M | 5.05M | 7.21M | 7.14M | 6.01M | 4.33M |
| Deferred Tax Liabilities | -3.15M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -56K | 0 | 10.86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.25M | 3.02M | 34.14M | 21.39M | 8.78M | 14.82M | 18.79M | 22.18M | 28.82M | 155.38M |
| Total Debt | 4.61M | 0 | 279K | 54K | 1.65M | 5.91M | 8.19M | 8.23M | 7.32M | 6.31M |
| Net Debt | -17.16M | -30.95M | -50.78M | -31.95M | -14.14M | -44.68M | -22.54M | -48.01M | -24.47M | -92.34M |
| Debt / Equity | 0.21x | - | 0.01x | 0.00x | 0.02x | 0.02x | 0.04x | 0.05x | 0.04x | 0.07x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - | -32.50x |
| Total Equity | 21.5M | 31.33M | 27.25M | 96.74M | 83.75M | 257.19M | 185.09M | 161.03M | 206.58M | 95.39M |
| Equity Growth % | 1.49% | 0.46% | -0.13% | 2.55% | -0.13% | 2.07% | -0.28% | -0.13% | 0.28% | -0.54% |
| Book Value per Share | 4.51 | 3.23 | 2.64 | 6.41 | 4.72 | 13.47 | 7.56 | 5.77 | 5.62 | 1.92 |
| Total Shareholders' Equity | 21.5M | 31.33M | 27.25M | 96.74M | 83.75M | 257.19M | 185.09M | 161.03M | 206.58M | 95.39M |
| Common Stock | 3K | 10K | 11K | 17K | 18K | 24K | 25K | 34K | 42K | 50K |
| Retained Earnings | -37.25M | -55.85M | -71.66M | -92.48M | -121.59M | -167.84M | -250.18M | -343.08M | -469.73M | -653.17M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -75K | -2.64M | -1.11M | -1.93M | -1.88M | -1.43M | -3.86M | -3.06M | -3.49M | -5.21M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -13.16M | -23.72M | 10.56M | -36.37M | -44.82M | -30.17M | -78.13M | -75.26M | -89.23M | -152.91M |
| Operating CF Margin % | -6.17% | -15.77% | 1.26% | -2.25% | -3.53% | - | - | - | - | - |
| Operating CF Growth % | -1.07% | -0.8% | 1.45% | -4.44% | -0.23% | 0.33% | -1.59% | 0.04% | -0.19% | -0.71% |
| Net Income | -11.44M | -18.6M | -15.8M | -20.82M | -29.12M | -46.24M | -82.34M | -92.91M | -126.64M | -183.44M |
| Depreciation & Amortization | 33K | 40K | 180K | 378K | 512K | 537K | 743K | 718K | 816K | 941K |
| Stock-Based Compensation | 118K | 394K | 1.06M | 2.97M | 4.45M | 7.12M | 0 | 9.92M | 21.91M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | -33K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.66M | -1.37M | -651K | -103K | 13K | 72K | 15.78M | -407K | -485K | 14.56M |
| Working Capital Changes | -210K | -4.18M | 25.77M | -18.79M | -20.64M | 8.35M | -12.32M | 7.41M | 15.17M | 15.04M |
| Change in Receivables | -137 | -571K | -3.94M | -4.88M | -5.78M | 7.46M | -5.2M | -2.32M | 8.18M | -3.62M |
| Change in Inventory | 0 | 0 | 0 | 4.88M | 5.78M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 374K | -1.6M | 217K | 1.53M | -1M | 150K | 1.69M | 1.11M | 4.32M | -4.97M |
| Cash from Investing | -11K | 34.06M | -1.43M | -69.42M | 16.75M | -147.65M | 57.86M | 41.41M | -84.72M | 91.02M |
| Capital Expenditures | -11K | -74K | -1.43M | -1.08M | -220K | -82K | -931K | -1.2M | -42K | -929K |
| CapEx % of Revenue | 0.01% | 0.05% | 0.17% | 0.07% | 0.02% | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -715K | 34.14M | -1.43M | -69.42M | 16.75M | 0 | 0 | 0 | -401K | 0 |
| Cash from Financing | 33M | 2K | 8.99M | 87.94M | 11.58M | 212.12M | 1.58M | 58.12M | 150.71M | 159.73M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 33M | 2K | 0 | 242K | 216K | 1.53M | 0 | 1.53M | 53.77M | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -13.17M | -23.8M | 9.13M | -37.45M | -45.04M | -30.25M | -79.06M | -76.46M | -89.67M | -153.34M |
| FCF Margin % | -6.17% | -15.82% | 1.09% | -2.32% | -3.55% | - | - | - | - | - |
| FCF Growth % | -1.03% | -0.81% | 1.38% | -5.1% | -0.2% | 0.33% | -1.61% | 0.03% | -0.17% | -0.71% |
| FCF per Share | -2.76 | -2.45 | 0.88 | -2.48 | -2.54 | -1.58 | -3.23 | -2.74 | -2.44 | -3.09 |
| FCF Conversion (FCF/Net Income) | 1.15x | 1.28x | -0.67x | 1.75x | 1.54x | 0.65x | 0.95x | 0.81x | 0.70x | 0.83x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -53.2% | -70.44% | -53.96% | -33.58% | -32.26% | -27.13% | -37.23% | -53.69% | -68.9% | -121.5% |
| Return on Invested Capital (ROIC) | - | -710.23% | - | -108.4% | -45.24% | -30.8% | -38.64% | -60.35% | -71.38% | -152.29% |
| Gross Margin | 99.31% | 99.16% | 99.78% | 99.78% | -216.74% | - | - | - | - | - |
| Net Margin | -536.15% | -1236.9% | -188.29% | -129.08% | -229.44% | - | - | - | - | - |
| Debt / Equity | 0.21x | - | 0.01x | 0.00x | 0.02x | 0.02x | 0.04x | 0.05x | 0.04x | 0.07x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | -32.50x |
| FCF Conversion | 1.15x | 1.28x | -0.67x | 1.75x | 1.54x | 0.65x | 0.95x | 0.81x | 0.70x | 0.83x |
| Revenue Growth | 18.24% | -29.49% | 458.11% | 92.13% | -21.31% | -100% | - | - | - | - |
KalVista Pharmaceuticals, Inc. (KALV) reported $15.1M in revenue for fiscal year 2025. This represents a 883% increase from $1.5M in 2013.
KalVista Pharmaceuticals, Inc. (KALV) grew revenue by 0.0% over the past year. Growth has been modest.
KalVista Pharmaceuticals, Inc. (KALV) reported a net loss of $210.3M for fiscal year 2025.
KalVista Pharmaceuticals, Inc. (KALV) has a return on equity (ROE) of -121.5%. Negative ROE indicates the company is unprofitable.
KalVista Pharmaceuticals, Inc. (KALV) had negative free cash flow of $160.3M in fiscal year 2025, likely due to heavy capital investments.